ArticleWorld journal of nephrology2026
Efficacy of finerenone in reducing proteinuria in diabetic kidney disease with maximum tolerable doses of dapagliflozin and telmisartan.
Article in World journal of nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetic kidney disease (DKD) remains a leading cause of end-stage renal disease (ESRD), with persistent proteinuria contributing to renal and cardiovascular complications. Despite dual therapy with renin-angiotensin-aldosterone system (RAAS) blockers and sodium-glucose co-transporter-2 inhibitors (SGLT2is), residual proteinuria persists in a substantial subset of patients. Finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, has shown promise in reducing albuminuria and slowing chronic kidney disease progression. This study evaluated the additive effect of finerenone exclusively in patients receiving maximum tolerable doses of both dapagliflozin and telmisartan unlike previously available studies evaluating its effect on patients with maximum tolerated dose of angiotensin receptor blocker alone.
aimTo evaluate the efficacy and safety of finerenone in reducing proteinuria in patients with DKD who were receiving maximally tolerated doses of dapagliflozin and telmisartan.
methodsA retrospective, single-center observational study evaluated 33 patients with DKD and residual proteinuria. All patients received finerenone 10 mg daily for 24 weeks. Key parameters assessed at baseline and follow-up included urinary albumin-to-creatinine ratio (UACR), estimated glomerular filtration rate, and serum potassium. Responders were defined as patients who exhibited a reduction in UACR at follow-up.
resultsThe mean reduction in UACR was 9.5% (
conclusionFinerenone was associated with an overall reduction in albuminuria, with the magnitude of response varying according to baseline UACR. Greater proportional reductions were observed in patients with lower baseline albuminuria, while patients with moderate to severe albuminuria demonstrated a more heterogeneous response, including both responders and non-responders. Despite this variability, finerenone was generally safe and well tolerated. These findings support the use of finerenone as part of a multimodal strategy for proteinuria management in DKD, particularly as add-on therapy in patients receiving optimized RAAS blockade and SGLT2 inhibition, with the greatest benefit seen when introduced earlier in the course of albuminuric disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.